SCHEMBL13614223

SCHEMBL13614223

CCOC(=O)[C@](C)(N)CCc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.52
FFAR4 Q5NUL3 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
LMNA P02545 1/20 0.52
LTB4R Q15722 1/20 0.50
LTB4R2 Q9NPC1 1/20 0.50
NR1H4 Q96RI1 1/20 0.50
ALDH1A1 P00352 1/20 0.50
ALOX5 P09917 3/20 0.49
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
MAOB P27338 1/20 0.47
PARP10 Q53GL7 1/20 0.47
LTA4H P09960 1/20 0.47
EPHX2 P34913 1/20 0.47
PRKCA P17252 1/20 0.46
PRKCD Q05655 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7714028 0.88 FFAR1 (0.55) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL7619725 0.85 FFAR1 (0.52) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL8505531 0.85 FFAR1 (0.52) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL7712069 0.84 FFAR1 (0.53) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL13628909 0.84 S1PR1 (0.59) L3MBTL1LMNAKDM4E
Potassium Ion SCHEMBL7619825 0.82 L3MBTL1 (0.49) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL7617244 0.81 NPC1 (0.50) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL6713395 0.80 ALOX5 (0.52) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL1497875 0.80 ALDH1A1 (0.60) FFAR1FFAR4L3MBTL1LMNALTB4R
SCHEMBL3108951 0.80 ALDH1A1 (0.47) FFAR1FFAR4L3MBTL1LMNALTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612238-B2 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases NOVARTIS AG (CH) 2009-11-03 US disclosed